Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.

Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany.
The Journal of Immunology (Impact Factor: 5.36). 06/2011; 187(2):1047-56. DOI: 10.4049/jimmunol.1002460
Source: PubMed

ABSTRACT The aim of this study was to investigate whether the specific T cell response against the multiple myeloma Ag HM1.24 is enhanced by the immunomodulatory drug lenalidomide (Revlimid). Ag-specific CD3(+)CD8(+) T cells against the HM1.24 Ag were expanded in vitro by dendritic cells in 29 healthy donors and 26 patients with plasma cell dyscrasias. Ag-specific activation was analyzed by IFN-γ, granzyme B, and perforin secretion using ELISA, ELISPOT assay, and intracellular staining, and generation of Ag-specific T cells was analyzed by tetramer staining. Expression of T cell maturation markers (CD45RA, CD45R0, CCR7, and CD28) was investigated by flow cytometry. We found that activation of HM1.24-specific T cells from healthy donors and patients with plasma cell dyscrasias was enhanced significantly by lenalidomide and furthermore that the impact of lenalidomide on T cells depends on the duration of the exposure. Notably, lenalidomide supports the downregulation of CD45RA on T cells upon activation, observed in healthy donors and in patients in vitro and also in patients during lenalidomide therapy in vivo. We showed for the first time, to our knowledge, that lenalidomide enhances the Ag-specific activation of T cells and the subsequent downregulation of CD45RA expression of T cells in vitro and in vivo.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Lenalidomide activates the immune system, but the exact immunomodulatory mechanisms of lenalidomide in vivo are poorly defined. In an observational study we assessed the impact of lenalidomide on different populations of immune cells in multiple myeloma patients. Lenalidomide therapy was associated with increased amounts of a CD8+ T cell subset, phenotypically staged between classical central memory T cells (TCM) and effector memory T cells (TEM), consequently termed TCM/TEM. The moderate expression of perforin/granzyme and phenotypic profile of these cells identifies them as not yet terminally differentiated, which makes them promising candidates for the anti-tumor response. In addition, lenalidomide-treated patients showed higher abundance of CD14+ myeloid cells co-expressing CD15. This population was able to inhibit both CD4+ and CD8+ T cell proliferation in vitro and could thus be defined as a yet undescribed novel myeloid-derived suppressor cell (MDSC) subtype. We observed a striking correlation between levels of TCM/TEM, mature Tregs and CD14+CD15+ MDSCs. In summary, lenalidomide induces both activating and inhibitory components of the immune system, indicating the existence of potential counter-regulatory mechanisms. These findings provide new insights into the immunomodulatory action of lenalidomide.
    Clinical & Experimental Immunology 04/2014; 177(2). DOI:10.1111/cei.12343 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer testis antigens are immunotherapeutical targets aberrantly expressed on multiple myeloma cells, especially at later stages, when a concomitant immunoparesis hampers vaccination approaches. We assessed the expression of the multiple myeloma antigen HM1.24 (reported present in all malignant plasma-cells) and the cancer testis antigens MAGE-A2/A3 and NY-ESO-1 (aberrantly expressed in a subset of myeloma patients), in CD138-purified myeloma cells by qRT-PCR (n=149). In a next step, we analyzed the antigen-specific T-cell responses against these antigens by IFN-γ EliSpot-assay (n=145) and granzymeB ELISA (n=62) in relation to stage (tumor load) and expression of the respective antigen. HM1.24 is expressed in all plasma-cell samples, whereas cancer testis antigens are significantly more frequent in later stages. HM1.24 specific T-cell responses, representing the immunological status, significantly decreased from healthy donors to advanced disease. For the cancer testis antigens, the probability of T-cell responses increased in early and advanced stages compared to healthy donors, paralleling increased probability of expression. In advanced stages, T-cell responses decreased due to immunoparesis. In conclusion, specific T-cell responses in myeloma are triggered by antigen-expression but suppressed by tumor load. Future cancer testis antigen-based immunotherpeutical approaches might target early plasmacell-diseases to establish prophylactically a specific T-cell response against late stage antigens in immunocompetent patients.
    Clinical Cancer Research 01/2015; DOI:10.1158/1078-0432.CCR-14-1618 · 8.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) still remains an incurable disease, at least because of the existence of cell-adhesion mediated drug-resistant MM cells and/or continuous recruitment of presumed MM cancer stem cell-like cells (CSCs). As a new alternative treatment modality, immunological approaches using monoclonal antibodies (mAbs) and/or cytotoxic T lymphocytes (CTLs) are now attracting much attention as a novel strategy attacking MM cells. We have identified that HM1.24 [also known as bone marrow stromal cell antigen 2 (BST2) or CD317] is overexpressed on not only mature MM cells but also MM CSCs. We then have developed a humanized mAb to HM1.24 and defucosylated version of the mAb to adapt to clinical practice. Moreover, we have successfully induced HM1.24-specific CTLs against MM cells. The combination of these innovative therapeutic modalities may likely exert an anti-MM activity by evading the drug resistance mechanism and eliminating presumed CSCs in MM.
    BioMed Research International 07/2014; 2014:965384. DOI:10.1155/2014/965384 · 2.71 Impact Factor
    This article is viewable in ResearchGate's enriched format

Full-text (2 Sources)

Available from
May 28, 2014